BioTech Medics Announces SHBAN Antiviral Solution Undergoing H1N1 (Swine) Influenza Efficacy Testing

DALLAS, TX, Jul 14 (MARKET WIRE) --
BioTech Medics, Inc. (PINKSHEETS: BMCS) announces that it has contracted
to start conducting independent clinical testing of its patented
SHBAN(TM) Antiviral Hand Sanitizer Solution to prove it kills the H1N1
(Swine) Influenza A virus in compliance with FDA and EPA standards.

In 2007 BioTech conducted an independent study to determine the efficacy
of virucidal SHBAN against Avian H5N1 Influenza NIBRG-14 Virus (also
known as the Avian Bird Flu). BioTech reported that the SHBAN Solution had
clinically proven its anti-viral properties and had topically killed the
Avian Influenza virus. Significantly, SHBAN was proven non-toxic with "no
cytotoxicity observed on the MDCK cell line after treatment."

SHBAN is a bio-degradable product superior to most anti-viral and
anti-bacterial disinfectants because 1) SHBAN is longer lasting, SHBAN
does not evaporate within 15 seconds after application and cease working
(like alcohol gels); 2) SHBAN is non-toxic when used as directed on
humans and animals; 3) SHBAN is non-staining, non-bleaching; 4) SHBAN is
non-flammable and 5) SHBAN has no harmful or toxic odors. Most hand
sanitizer products cannot make all of these claims.

BioTech currently sells a 3 oz SHBAN(TM) Go Anywhere Hand Atomizer Spray
Bottle that complies with TSA carry-on travel regulations. SHBAN sales are
up significantly in 2009. BioTech is releasing this Fall 1 oz and 16 oz
bottles together with SHBAN Hand Wipe Towelettes.

The World Health Organization (WHO) has declared the H1N1 Influenza a
worldwide pandemic 6, so it is essential that people buying hand
sanitizers know that SHBAN can prove that SHBAN kills the H1N1 Influenza
Virus on the hands. SHBAN is protected under US Letters of Patent
#5,514,808, #5,574,050, #5,679,711 and #5,585,391 and pending
international patents. SHBAN is a trademark of BioTech Medics, Inc.
BioTech is seeking and negotiating USA and foreign distributorships at
this time.

SHBAN(TM) in previous in vitro and in vivo testing has been evaluated for
its antimicrobial properties against Staph. Aureus, Staph. Epidermidis,
EC. Faecalis, E. Coli and Ps. Aeruginosa.

Safe Harbor: Forward-Looking Statements

This release contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995 (the "Act"). The
statements above have not been evaluated by the FDA. SHBAN is not intended
to diagnose, treat or cure any disease.

Contact:
Tom Wood
Sr. V.P. Sales
Phone 972-849-3782

Copyright 2009, Market Wire, All rights reserved.

-0-